Anbio Biotechnology (NNNN) Payables (2023 - 2025)

Anbio Biotechnology (NNNN) has 3 years of Payables data on file, last reported at $60.4 billion in Q2 2025.

• On a quarterly basis, Payables changed N/A year-over-year to $60.4 billion in Q2 2025; TTM through Jun 2025 was $60.4 billion, a N/A change from a year earlier, with the FY2024 full-year figure at $1.6 million, up 96.49% from the prior year.
• Payables for Q2 2025 stood at $60.4 billion, up from $1.6 million in the prior quarter.
• Over the last five years, Payables for NNNN reached as high as $60.4 billion in Q2 2025 and fell as low as $827151.0 in Q4 2023.
• Historically, Payables has averaged $20.1 billion across 3 years, with a median of $1.6 million in 2024.
• On a YoY basis, Payables climbed as much as 96.49% in 2024 and fell as far as 96.49% in 2024.
• Year by year, Payables stood at $827151.0 in 2023, then jumped by 96.49% to $1.6 million in 2024, then jumped by 3713163.46% to $60.4 billion in 2025.
• Per Business Quant data, the three most recent Payables figures were $60.4 billion in Q2 2025, $1.6 million in Q4 2024, and $827151.0 in Q4 2023.